499 related articles for article (PubMed ID: 19671802)
21. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
22. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
Lebwohl M; Yeilding N; Szapary P; Wang Y; Li S; Zhu Y; Reich K; Langley RG; Papp KA
J Am Acad Dermatol; 2010 Oct; 63(4):571-9. PubMed ID: 20599293
[TBL] [Abstract][Full Text] [Related]
23. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Uhlenhake EE; Feldman SR
Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
[TBL] [Abstract][Full Text] [Related]
25. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
26. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
29. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
[TBL] [Abstract][Full Text] [Related]
31. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
Guenther L; Han C; Szapary P; Schenkel B; Poulin Y; Bourcier M; Ortonne JP; Sofen HL
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):851-7. PubMed ID: 21521375
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
33. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE; Girolomoni G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
[TBL] [Abstract][Full Text] [Related]
35. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
[TBL] [Abstract][Full Text] [Related]
36. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
Farhi D
Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab for the treatment of psoriasis.
Laws PM; Warren RB
Expert Rev Clin Immunol; 2011 Mar; 7(2):155-64. PubMed ID: 21426253
[TBL] [Abstract][Full Text] [Related]
38. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
39. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Howell ST; Cardwell LA; Feldman SR
Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
[TBL] [Abstract][Full Text] [Related]
40. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
